Why the study?
Does azilsartan medoxomil improve 24-hour BP control compared to other antihypertensive drugs in patients with arterial hypertension?
Does azilsartan medoxomil improve 24-hour BP control compared to other antihypertensive drugs in patients with arterial hypertension?
Azilsartan medoxomil is an effective and well-tolerated ARB for 24-hour blood pressure control, offering potential pleiotropic benefits in patients with metabolic comorbidities.
Supports azilsartan as an effective ARB for sustained blood pressure management; leaves open.
Azilsartan medoxomil is a drug from class of angiotensin II receptor antagonist (sartans), have a antihypertensive effect and excellent tolerability profile. In comparison with other drugs (candesartan, olmesartan, ramipril, chlorthalidone, valsartan) according to comparative studies and meta-analyses azilsartan medoxomil demonstrated high antihypertensive efficacy, in terms of 24-hour BP control, which allows to recommend its purpose in patients of hypertension 1-2 degrees. This is due to the ability of the drug not only safely reduce AD during day and night hours, but also to normalize the circadian profile. Pleiotropic effects of azilsartan medoxomil in the form of increased sensitivity of receptors to insulin, a positive effect on glucose metabolism, improved endothelial function allow us to consider its purpose in patients with carbohydrate metabolism disorders, overweight, obesity, and metabolic syndrome. The drug is indicated for as patients who have not previously received antihypertensive therapy and if previous treatment with other RAAS blockers did not lead to reliable achievement of target BP levels. High efficiency and safety of azilsartan medoxomil can provide better patient adherence to long term therapy and achieve optimal results of therapy.
No takes yet. Share an insight, caveat, or question.
Martynyuk et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: